test

The Authority

The Authority

The Authority

Traverse Biosciences Executes Agreement with Aratana for Periodontal Disease in Dogs and Cats

Animal Health published Wed, 2015-05-06 09:26

Stony Brook, NY; May 4, 2015: Traverse Biosciences announced today that it has executed a $250,000 cooperative research and development agreement (CRADA) with Kansas-based Aratana Therapeutics Inc. (NASDAQ:PETX) to advance the development of TRB-N0224 for the treatment and control of periodontal disease in companion animals, including dogs and cats. 

The funds provided by Aratana under the CRADA will be used by Traverse Biosciences primarily to conduct a proof-of-concept (POC) efficacy study to evaluate TRB-N0224, a proprietary chemically-modified curcumin, in an accepted animal model of canine periodontal disease. Canine periodontal disease affects approximately 80% of dogs by age three, with the highest incidence in smaller breeds and older animals. Periodontal disease in dogs, of which there are approximately 83 million pets in the U.S. alone, leads to serious oral health complications, and can impair liver, kidney, cardiac and metabolic function. Traverse Biosciences also intends to conduct pilot pharmacokinetic, pre-formulation and preliminary safety studies during the term of the agreement.

Mr. Joseph Scaduto, Founder and CEO of Traverse Biosciences, stated, “The global animal health market is rapidly expanding, and this growth represents a significant business opportunity for companies developing innovative products that address unmet needs in veterinary medicine. We are very fortunate and excited to engage with Aratana Therapeutics to accelerate the commercialization of TRB-N0224 for the treatment and control of periodontal disease in companion animals.”

Dr. Steven St. Peter, Founder, President and CEO of Aratana Therapeutics, commented, “We are pleased to initiate this strategic partnership with Traverse Biosciences given the opportunity that TRB-N0224 represents as a potential therapeutic for periodontal disease in dogs and cats.  Aratana is committed to providing veterinarians with new therapies that are deeply rooted in science, and which are specifically made for pets.  Our pipeline currently consists of more than 18 therapies to treat a variety of diseases affecting companion animals. TRB-N0224 would be the first product to treat an oral health condition.”

 

Read the full announcement here.

 

Share

AAD announces three new board members

Animal Health published Thu, 2015-03-26 16:30

Advanced Animal Diagnostics (AAD) has recently added three individuals to its board of directors, following the recent close of its $15 million Series C round of equity financing. Bob Shapiro, managing director of Cultivian Sandbox Ventures; Tony Simpson, managing director of Kansas Bioscience Authority; and Dennis Dougherty, managing general partner of Intersouth Partners joined the board of directors to guide AAD, a developer of rapid on-farm diagnostic technologies.  

 

AAD provides diagnostics that detect disease early and accurately, empowering livestock producers to make real-time management decisions that increase productivity, prevent losses, improve animal welfare and protect the food supply. AAD developed and launched QScout® MLD (milk leukocyte differential) test for early detection of subclinical mastitis in dairy cows, along with QScout® Farm Lab which reads QScout MLD and other rapid, on-farm tests in development.

 

“We are fortunate to augment our board with these visionary leaders,” says AAD CEO Joy Parr Drach. “Each brings distinct and deep experience in developing innovative agricultural and life sciences companies.”

 

Shapiro, whose Illinois-based Cultivian Sandbox Ventures invests in emerging technologies that address agriculture’s biggest challenges, says AAD fits well into their mission as investors as it offers advanced technologies that help livestock producers manage their animals better and run more efficiently as a business.

 

“What’s most important about AAD technology is it provides early diagnosis of disease, and therefore better prospects for treatment,” continues Shapiro, former Monsanto CEO. “As with human diagnostics, we want early indications so we can treat diseases more efficiently and minimize their damage. Applying these advanced technologies to the health of animals raised to provide nutrition to humans is of great importance to livestock producers in this country and around the word, and to all of us as consumers.”

 

Shapiro is the co-founder and managing director of Sandbox Industries, a venture capital firm that partners with Cultivian Sandbox for investments in food and agriculture technology. He is the former chairman of Pharmacia, chairman and CEO of Monsanto, and chairman and CEO of The NutraSweet Company. He previously served as vice president and general counsel of G.D. Searle & Company and General Instrument Corporation. Prior to this, he practiced law in New York City and was a professor of law at Northeastern University in Boston and the University of Wisconsin-Madison. He is a Fellow of the American Academy of Arts and Sciences.

 

Simpson spent nine years with POET, where he started two major green-field ethanol plants and led equity drives, refinancings and expansion efforts for these facilities. Before that, he held positions at ADM in trading and plant operations management. He also served as general manager for ED&F Man’s ethanol operations in the United States, leading asset management and business development efforts. Simpson serves on the selection committee for the Animal Health Investment Forum, chairs the selection committee for the ag, food and bioenergy tract for InvestMidwest Venture Capital Forum, and is a member of Global AgTech Investors Network.

 

Dougherty founded Intersouth Partners in 1985 and led investments in ag companies like Athenix and Paradigm Genetics. Previously, Dougherty was an office managing partner and head of the high growth business practice for Touche Ross & Co. Dougherty is active in the venture industry, having served on the National Venture Capital Association board of directors and Kauffman Fellows Program steering committee. He was a mentor for two classes of Kauffman Fellows, and served on the North Carolina State University Seed Fund board and Governor’s Biotechnology Steering Committee. He was a founder of the Council for Entrepreneurial Development and chair of its first Venture Conference.
 

They join AAD board members Steve Weinstein, managing director of the Novartis Venture Fund; Ben Shelton, DVM, owner of Rocky Creek Dairy and Rocky Creek Veterinary Service; Joy Parr Drach, AAD president and CEO; and chairman of the board Randall Marcuson.   
 

About Advanced Animal Diagnostics

Advanced Animal Diagnostics (AAD), Durham, N.C., provides livestock producers with diagnostics that improve profitability and empower more precise care of animals so they live healthier, more productive lives. AAD is committed to researching, developing and commercializing the industry’s most reliable, on-farm diagnostic tests, such as QScout MLD test for early detection of subclinical mastitis in dairy cows. With its diagnostic offerings, the company aims to empower real-time management decisions that increase productivity, prevent losses, improve animal welfare and protect the food supply. For more information, visit www.QScoutLab.com.

 

Share

Advanced Animal Diagnostics Closes $15 Million in Oversubscribed Series C Funding

Animal Health published Mon, 2015-02-23 17:46

DURHAM, NC — December 8, 2014 — Advanced Animal Diagnostics (AAD) announced today the close of a $15 million Series C round of equity financing. The financing was co-led by the Kansas Bioscience Authority and CultivianSandbox and included Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), Middleland Capital, and existing investors Intersouth Partners, Novartis Venture Funds and private individuals. The investment will allow AAD to accelerate the commercialization of its current product offering, QScout® MLD (milk leukocyte differential) test, while also expanding the company’s product line.

AAD develops on-farm diagnostic technologies that change the way livestock producers manage animal health and costly diseases. The company launched its first commercial products, QScout MLD test and QScout Farm Lab, in 2013 to detect subclinical mastitis in dairy cows. Large-scale trials on commercial dairies demonstrated that the technology significantly improves producers’ financial returns by preventing milk and reproductive losses, safeguarding animal health through earlier detection and promoting more judicious use of antibiotics. 

“Investors and our growing number of customers see value in rapid, on-farm diagnostic information that hasn’t existed before,” said Joy Parr Drach, AAD president and CEO. “This new information allows producers to make more accurate management decisions to improve animal health and their bottom line while ensuring they use antibiotics only when needed to provide the best quality product for consumers.”

AAD customer John Freund of Son-Bow Farms in Wisconsin said QScout MLD is a significant improvement over conventional tests. “QScout MLD gives us a better, consistent approach for diagnosing subclinical mastitis, and it is more efficient for our labor flow compared to on-farm culture tests. The test’s objective results create a tremendous opportunity to address an issue, improve the quality of milk going into the tank, and provide a better product for consumers.”

The company expects to advance the development of additional livestock tests for dairy and beef markets, invest in production and manufacturing, and expand commercial efforts for new and existing customers with this financing.

About Advanced Animal Diagnostics
Advanced Animal Diagnostics (AAD), Durham, N.C., provides livestock producers with diagnostics that improve profitability and empower more precise care of animals so they live healthier, more productive lives. AAD is committed to researching, developing and commercializing the industry’s most reliable, on-farm diagnostic tests, such as QScout MLD for early detection of subclinical mastitis in dairy cows. With its diagnostic offerings, the company aims to empower real-time management decisions that increase productivity, prevent losses, improve animal welfare and protect the food supply. For more information, visit www.QScoutLab.com or call 1-855 Q2COUNT.

About the Investors:

Kansas Bioscience Authority
Kansas Bioscience Authority is a venture investor focused in agribusiness, animal health, and human health innovations. The team brings deep sector expertise and co-investors together to accelerate bioscience company growth generating results for the entrepreneur, the investor, Kansas and the world. For more information, please visit www.kansasbioauthority.org.

Cultivian Sandbox
Cultivian Sandbox is a venture capital fund focused on high-technology opportunities in the food and agricultural sectors. Cultivian Sandbox operates from the Midwest, which hosts the world’s greatest concentration of public and private R&D spending for food and agricultural markets. Cultivian Sandbox works closely with the management of emerging technology companies to bring cutting-edge technology solutions to market. The fund focuses on investments in the following areas: animal health, biobased products and processes, environmental technologies, food safety, human wellness, and production technologies. For more information, please visit www.cultiviansbx.com. 

LabCorp
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group:  The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox, and Endocrine Sciences.  LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. For more information, please visit www.labcorp.com.

Middleland Capital
Middleland Capital is a private investment firm focused on global early-stage technology  opportunities. Leveraging a unique breadth of geographic and industry experience, the firm seeks partnerships with exceptional management teams to commercialize innovative technologies, accelerate growth and build long-term value around the world. For more information, please visit www.middlelandcap.com.

Intersouth Partners 
Intersouth Partners is one of the most active and experienced venture capital firms in the Southeast, having invested in more than 100 private companies. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast. For more information, please visit www.intersouth.com.

Novartis Venture Funds
Established in 1996, the Novartis Venture Fund currently manages over $800 million in committed capital and is invested globally in more than 55 private life sciences companies across biotech, medical devices and diagnostics. As a financially driven corporate life science investor, the Novartis Venture Fund invests in those companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to the patient.  For more information, please visit www.venturefund.novartis.com.

Share

Aratana licenses treatment for dogs with atopic dermatitis

Animal Health published Mon, 2015-02-23 17:50

Aratana Therapeutics Inc. has finalized a global licensing agreement with Ukraine-based Atopix Therapeutics Ltd. to develop and commercialize a drug for dogs to treat atopic dermatitis, also known as eczema.

Atopix is continuing to study the drug's use in humans to treat moderate to severe atopic dermatitis and is currently in a Phase 2 study of its drug, OC459.

"We believe this product fits nicely into our portfolio of companion animal therapeutics," Aratana CEO Steven St. Peter said in a release. "We continue to be committed to developing products that target the underlying cause of the disease rather than just the symptoms."

The Kansas City, Kan., animal health company (Nasdaq: PETX) paid $1 million to Atopix for the rights to all non-human health applications. Atopix will receive additional payments, such as royalties, as Aratana reaches "regulatory milestones."

- Leslie Collins,  Kansas City Business Journal

 

Share

Aratana seeks more than $40M in latest public stock offering

Animal Health published Thu, 2014-09-18 09:59

Aratana Therapeutics Inc. announced Wednesday it will offer 4.5 million shares of its common stock at $9.25 a share, which would raise about $41.6 million.

The Kansas City, Kan., animal health company announced its third public stock offering Wednesday.

According to information filed with the Securities and Exchange Commission, Aratana (Nasdaq: PETX) plans to use a portion of the proceeds to expand its commercial infrastructure in anticipation of future product launches. It also may use the money to in-license or acquire additional technologies or businesses, and continue development of its current technologies.

Aratana has spent the last year actively acquiring new companies and technologies to build its pipeline of therapies for companion animals.

In October 2013 the company entered the canine cancer business with its acquisition of San Diego-based Vet Therapeutics Inc.

Shortly after, it announced it had purchased Belgium-based Okapi Sciences, which is developing a handful of clinical-stage therapeutics for treating viral diseases in companion animals.

Later in 2014, Aratana licensed the right to commercialize human cancer products owned by Advaxis Inc. for use in pets. It also licensed a stem cell therapy from Vet-Stem Inc. that it plans to develop to treat osteoarthritis in dogs.

Reported by:

- Brianne Pfannenstiel, Kansas City Business Journal

Share

KC Animal Health Corridor Grows to Represent 56 Percent of Global Industry Sales

Animal Health published Tue, 2014-08-26 09:54

New survey reveals increased corporate presence in KC region

August 25, 2014The Kansas City Animal Health Corridor has released new evidence of the global impact of the KC region’s animal health industry concentration. Companies with a strategic location in the KC Animal Health Corridor now represent 56 percent of total worldwide animal health, diagnostics and pet food sales.

The new evidence results from a recent asset survey, unveiled to 850 animal health industry leaders attending tonight’s 9th Annual KC Animal Health Corridor Homecoming.

“This latest survey is a powerful endorsement of nearly a decade of cooperation, teamwork and strategic focus that has driven the activities of the KC Animal Health Corridor effort since 2006,” said Scott Bormann, Corridor Advisory Board chair and vice president of U.S. operations for Merck Animal Health.

Organic industry growth resulting from mergers/acquisitions and corporate expansions within the Corridor have contributed to the KC region’s growing industry concentration. In addition, strategic outreach by the Kansas City Area Development Council to recruit new animal health companies to the region continues to be successful.

“We are so proud of the regional partnership that exists among the economic development, civic, corporate, academic and governmental leadership in the KC Animal Health Corridor,” said Kimberly Young, vice president of bioscience development at the Kansas City Area Development Council. “We are widely recognized as the strongest and most admired team in the global animal health industry.”

Since the KC Animal Health Corridor launched in 2006, 31 animal health companies have located in the KC Animal Health Corridor. These companies have pledged to create 1,368 new jobs resulting in $78.6 million in new payroll. They have made a total $872.5 million capital investment, occupying 1,054,138 million sq. ft. of new space.

A stable base of animal health companies with a U.S. headquarters in the KC Animal Health Corridor has provided a strong foundation for new industry growth. Companies with a U.S. headquarters located within the Kansas City Animal Health Corridor now represent 29 percent of the worldwide sales of animal health products and diagnostics.

The 2014 KC Animal Health Corridor Asset Survey was conducted and analyzed by Axxiom Consulting.

About the KC Animal Health Corridor
The KC Animal Health Corridor, anchored by Manhattan, Kansas, and Columbia, Missouri, is home to more than 300 animal health companies, representing the largest concentration in the world. For more information, visit KCanimalhealth.com.

Share

Aratana Therapeutics Reports Second Quarter 2014 Results

Animal Health published Tue, 2014-08-12 14:39

KANSAS CITY, Kan., Aug. 12, 2014 /PRNewswire/ --  Aratana Therapeutics, Inc. PETX +7.07% , a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its second quarter 2014 results.

"We continue to advance our highly innovative pipeline," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics.  "This quarter, we were very pleased that we were able to file our third product for licensure – a cancer vaccine to treat dogs with osteosarcoma."

Aratana's diversified portfolio now consists of more than fifteen therapeutic candidates: two have received conditional licensure, one has been submitted for licensure, more than ten are in active development and several additional candidates are in pre-development.

Development Highlights:

  • Aratana is currently enrolling dogs in two studies investigating the use of AT-005, the Company's conditionally licensed monoclonal antibody for treatment of T-cell lymphoma, in combination with chemotherapy. Aratana continues to anticipate making AT-005 available commercially to a limited number of clinics in the fall of 2014.  After receipt of a full license for AT-005 from the United States Department of Agriculture (USDA), which Aratana continues to expect in 2015, commercial availability will be further expanded.

  • Aratana continues to anticipate full licensure from the USDA of AT-004 in 2014, the Company's conditionally licensed monoclonal antibody for the treatment of B-cell lymphoma.  AT-004 is partnered in the US and Canada.

  • AT-001 (grapiprant, EP4 receptor antagonist for osteoarthritis pain): Aratana continues to enroll the pivotal field effectiveness study in client-owned dogs; Aratana continues to anticipate top-line results in 2014 and first U.S. Food and Drug Administration (FDA) approval in 2016.  Aratana initiated a pilot field study in client-owned cats in the second quarter.

  • AT-002 (capromorelin, ghrelin agonist for appetite stimulation): Aratana continues to enroll the pivotal field effectiveness trial in client-owned dogs; Aratana continues to anticipate top-line results in the first quarter of 2015 and first FDA approval in 2016.  Aratana initiated a pilot field study in client-owned cats in the second quarter.

  • Aratana filed for a product license from the USDA for AT-014, a novel cancer immunotherapy for the treatment of canine osteosarcoma. This product was licensed exclusively from Advaxis, Inc. in March 2014.

  • AT-003 (bupivacaine extended release injectable suspension for post-operative pain): Aratana is near completion of  a pilot study in client-owned dogs and will be discussing the design of the pivotal field effectiveness with the FDA in coming months; Aratana continues to anticipate the first FDA approval in 2016.  Aratana expects to start a cat pilot lab study in the fourth quarter 2014. 

  • During the quarter, the Company licensed commercial rights to a novel, allogeneic stem cell therapy technology (AT-016).  This FDA-regulated therapy is being developed to allow stem cells from a single donor to be processed to generate more than 1 million doses that can be stored and used to treat multiple dogs with osteoarthritis.  A multi-center, placebo-controlled, dose confirmation study was recently initiated by Aratana's partner, Vet-Stem, Inc.

  • AT-006, the Company's partnered antiviral for treatment of ocular lesions associated with feline ocular herpes infection, closed enrollment on a partially-enrolled pivotal field study in Germany to harmonize the program to enable a concurrent US and EU development plan.  The closed study will not enable a pivotal submission in 2015. 

  • During the quarter, one of Aratana's two products in the Option Programs, the AT-Beta option period was extended until mid-2015. If Aratana elects to move AT-Beta into development it will be developed for seizures in dogs.

  • During the quarter, Aratana completed a proof-of-concept study for its AT-Gamma option program.  Aratana has delivered notice of its intent to exercise a license agreement, and anticipates completing the agreement in 2014.  AT-Gamma is a CRTh2 antagonist, which will be developed for atopic dermatitis in dogs.

  • During the second quarter, the Company presented three peer- reviewed abstracts at the American College of Veterinarians Internal Medicine (ACVIM) meeting; Aratana will be presenting three additional abstracts at the Veterinary Cancer Society meeting in October.

  • For more information, please visit www.aratana.com.

Share

Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma

Animal Health published Fri, 2014-06-20 11:20

KANSAS CITY, Kan., Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.

These studies are not required by the USDA to obtain a full product license for AT-005, for which it is currently under review. They were designed by veterinary oncologists to evaluate AT-005 under real practice conditions, which will help Aratana and oncologists understand the clinical value of AT-005 once it is fully licensed by the USDA, which is anticipated to be in 2015. Specifically, the studies will evaluate AT-005 in combination with two different chemotherapy regimens used to treat dogs diagnosed with intermediate- to high-grade peripheral T-cell lymphoma. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Aratana is committed to demonstrating the full clinical potential of our novel pet biologics, which may offer veterinarians a new paradigm for treating lymphoma in dogs. In addition to the positive safety and efficacy data upon which the USDA based our product licenses for our canine lymphoma monoclonal antibodies, we believe the results of these two market development studies will be instrumental for demonstrating the potential benefit of adding a biologic to standard chemotherapy. Similar regimens have had meaningful impact on patient outcomes in human drug development, and we believe our ability to demonstrate a similar effect for AT-005 will facilitate its adoption by veterinarians and pet owners."

The studies are being conducted in coordination with Animal Clinical Investigation, LLC (ACI).

This study is currently enrolling patients.  For more information, please visit http://www.animalci.com/trials/t-lab .

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes more than fifteen therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Share

Aratana Therapeutics licenses new stem cell therapy for arthritis in dogs

Animal Health published Fri, 2014-06-13 15:19

Aratana Therapeutics Inc. has licensed a new stem cell therapy that it plans to develop to treat osteoarthritis in dogs.

The agreement grants the Kansas City, Kan., animal health company the exclusive rights to commercialize the therapy from Vet-Stem Inc., a California veterinary regenerative medicine company.

Vet-Stem, according to a release, pioneered a process in which fat tissue is harvested from a patient before stem cells are isolated and then reintroduced back into that patient. The company also has developed a technology in which a single donor sample can be used to generate doses that can be stored and used to treat a number of patients.

Aratana licensed that therapy, which it will test for safety and efficacy in treating osteoarthritis in dogs.

"As we continue to build our pipeline, we have made a clear strategic investment in the high-need area of pain management for our pets," Aratana CEO Steven St. Peter said in a statement. "We therefore are pleased to expand our pain franchise further by adding an allogeneic, regenerative cell therapy product, which in addition to its aim of reducing the pain of osteoarthritis, has the potential to impact the progression of the disease, and to promote tissue regeneration. We will examine this phenomenon in planned studies, which could result in product labeling that specifies disease-modifying properties."

 

- The Kansas City Business Journal

 

Share

Aratana Therapeutics Reports First Quarter 2014 Results

Animal Health published Tue, 2014-06-03 16:21

KANSAS CITY, Kan., -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results.

"Aratana continues to advance its deep pipeline of therapeutics focused on treating serious diseases in pets," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "We are establishing ourselves as a leader in the rapidly evolving pet therapeutics industry."

 

Click here to view report.

 

 

 

 

 

Share

Aratana gains conditional approval for cancer drug

Animal Health published Tue, 2014-01-28 09:42

Aratana Therapeutics Inc. announced Tuesday that it has gained conditional approval to begin marketing a drug designed to treat cancer in dogs.

The USDA grants conditional approval for animal drugs that are proven to be safe but that have not yet been proven to be effective. However, there must be a "reasonable expectation" that the drug is effective.

This product, called AT-005 targeting T-cell lymphoma, is Aratana's second drug to gain that license.

A drug that is designed to treat B-cell lymphoma, called AT-004, gained that designation in 2012 and is currently licensed to Novartis Animal Health Inc.

Aratana acquired both drugs during the company's merger with San Diego company Vet Therapeutics Inc. in October 2013.

"We are proud to achieve our first regulatory milestone following the acquisition of Vet Therapeutics' pet biologics platform, which brings us closer to market with our first internal commercial opportunity," CEO Steven St. Peter said in a statement. "Conditional approval by the USDA for AT-005 is also a major milestone for our dog lymphoma franchise as a whole, which we believe is poised to redefine the treatment of this important disease that affects millions of dogs worldwide."

The company will now focus on gaining full licenses from the USDA for both products.

 

 

- Kansas City Business Journal Jan. 28, 2014

Share

Aratana Therapeutics is the recipient of KBA Investment

Animal Health published Wed, 2013-02-06 13:54

OLATHE, Kan. (February 6, 2013) – Aratana Therapeutics is the recipient of a $324,148 investment by the Kansas Bioscience Authority. Previously code-named “Project Gray,” the funding was unanimously approved by the Board of Directors on January 22, 2013.  Aratana requested that the details of this investment be kept confidential until the fundraising round closed.

Aratana Therapeutics is an animal health drug development company that delivers high-quality, new medicines for unmet needs in animal health.  Established in December 2010 in Kansas City, Kan., the company licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies.

The KBA funds will be invested in their Series C Preferred Stock to maintain the Authority’s ownership stake.

“This Series C offering gives the KBA the opportunity to provide important follow-on capital to one of the most successful equity investments in our portfolio,” said Duane Cantrell, KBA President and CEO.   “The initial investment in Aratana Therapeutics three years ago was successful in yielding $30 million in new equity investment in the state, which led to new jobs, increased research spending and the attraction of new animal health companies to Kansas.”

Share

Subscribe Via RSS

Recent Blog Posts

By Sector

Bioenergy Animal Health Human Health

Archive

2014

2013

2012

2011